Trial Profile
Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802 and Its Interaction With Food in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Vixotrigine (Primary)
- Indications Bipolar disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 29 Mar 2021 Results of Population PK model analysis from 12 clinical studies: SCB107718, SCB107727, SCB113210, SCB113210, 802HV101, 802HV102, 802HV104, 802HV105, 802HV106, 802HV107, 1014802/202, 1014802/201 and 1014802/205 published in the European Journal of Drug Metabolism and Pharmacokinetics
- 27 May 2009 New trial record